London, United Kingdom

Peter Ravn

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 27(Granted Patents)


Location History:

  • London, GB (2012 - 2016)
  • Cambridge, GB (2018)

Company Filing History:


Years Active: 2012-2018

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Peter Ravn

Introduction

Peter Ravn is a notable inventor based in London, GB. He has made significant contributions to the field of biotherapeutics, holding a total of 4 patents. His work focuses on developing innovative solutions for medical challenges, particularly in the areas of tumor recognition and metabolic disorders.

Latest Patents

Among his latest patents are the "Anti-PCSK9-GLP-1 fusions and methods for use," which provides novel fusions aimed at addressing metabolic issues. Another significant invention is the "Tumor-specific recognition molecules," which relates to molecules designed to target tumors, enhancing diagnosis and therapy for tumor diseases.

Career Highlights

Peter Ravn has worked with prominent companies in the biopharmaceutical sector, including Medimmune Limited and Nemod Biotherapeutics GmbH & Co. KG. His experience in these organizations has allowed him to contribute to groundbreaking research and development in therapeutic innovations.

Collaborations

Throughout his career, Peter has collaborated with esteemed colleagues such as Steffen Goletz and Antje Danielczyk. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Peter Ravn's contributions to the field of biotherapeutics exemplify the impact of innovative thinking in medicine. His patents and collaborations highlight the importance of research and development in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…